NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

LIPO

Lipella Pharmaceuticals Inc

Jun 30 • 03:59PM ET

0.8676

Dollar change -0.0324
Percentage change -3.60	%

Healthcare • Biotechnology • USA • NASD

Peers: VKTX EBS EYPT TVRD PTGX SCYX GOSS CPIX UBX HOOK

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.12	Insider Own	6.53%	Shs Outstand	4.47M	Perf Week	-21.13%
Market Cap	3.88M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.18M	Perf Month	-70.98%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	1.41%	Short Float	2.40%	Perf Quarter	-66.50%
Income	-	P/S	7.46	EPS this Y	-	Inst Trans	-	Short Ratio	1.13	Perf Half Y	-72.56%
Sales	0.52M	P/B	0.54	EPS next Y	-	ROA	-	Short Interest	0.10M	Perf YTD	-71.55%
Book/sh	1.60	P/C	-	EPS next 5Y	-	ROE	-	52W High	12.00 -92.77%	Perf Year	-76.97%
Cash/sh	-	P/FCF	-	EPS past 3/5Y	-22.58% -	ROIC	-	52W Low	0.62 39.71%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	27.41% -	Gross Margin	-	Volatility	33.39% 21.02%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	33.80%	Oper. Margin	-	ATR (14)	0.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	8.88%	Profit Margin	-	RSI (14)	22.58	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	-60.42%	Beta	0.02	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-11.30%	SMA50	-64.17%	Rel Volume	0.09	Prev Close	0.90
Employees	5	LT Debt/Eq	-	Earnings	-	SMA200	-69.39%	Avg Volume	88.31K	Price	0.87
IPO	Dec 20, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	-3.13% 0.00%	Trades		Volume	8,095	Change	-3.60%

Jun-25-25 03:15PM	Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting (GlobeNewswire) +14.62%
Jun-20-25 03:19PM	Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market (GlobeNewswire) -30.08%
Jun-17-25 08:30AM	Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology (GlobeNewswire) -5.75%
Jun-04-25 08:30AM	Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development (GlobeNewswire)
May-15-25 09:00AM	Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting (GlobeNewswire) -6.69%
08:30AM	Loading…
Apr-23-25 08:30AM	Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on Global Transformation in Oral Medicine (GlobeNewswire)
Apr-22-25 05:30AM	Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025 (GlobeNewswire) +5.04%
Apr-08-25 09:55AM	Lipella enrols all subjects in Phase IIa trial targeting oral lichen planus (Clinical Trials Arena)
05:00AM	Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus (GlobeNewswire)
Mar-31-25 11:00AM	Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast (GlobeNewswire)
Mar-07-25 04:56PM	Spartan Capital Securities, LLC Announces Key February Transactions (GlobeNewswire) -10.20%
Mar-04-25 01:18PM	Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.s $3,788,000 Private Placement (GlobeNewswire) -10.68%
Feb-11-25 10:52AM	Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes (Benzinga) +41.64%
05:46AM	Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus (GlobeNewswire)
Feb-06-25 06:00AM	Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus (GlobeNewswire) +80.23%
01:24PM	Loading…
Jan-10-25 01:24PM	Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement (GlobeNewswire) -8.52%
Dec-31-24 11:55AM	Spartan Capital Securities, LLC Caps Off a Remarkable Year with Key December Transactions (GlobeNewswire)
Dec-18-24 02:28PM	Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement (GlobeNewswire) -5.43%
Dec-03-24 08:30AM	Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus (GlobeNewswire) -8.20%
Nov-21-24 05:30AM	Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group (GlobeNewswire)
Nov-12-24 05:30AM	Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform (GlobeNewswire) -8.10%
Nov-01-24 04:30PM	Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split (GlobeNewswire) -12.80%
Oct-29-24 08:30AM	Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference (GlobeNewswire)
Oct-15-24 05:00AM	Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform (GlobeNewswire) +5.21%
Oct-09-24 10:47AM	Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-25-24 08:30AM	PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month (GlobeNewswire)
Sep-24-24 08:00AM	Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus (GlobeNewswire) +10.32%
Aug-27-24 08:00AM	Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York (GlobeNewswire)
Aug-22-24 05:00AM	Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research (GlobeNewswire)
Aug-21-24 05:00AM	Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference (GlobeNewswire)
06:52AM	Loading…
Aug-12-24 06:52AM	Lipella doses first two subjects in Phase IIa oral lichen planus treatment trial (Clinical Trials Arena)
05:00AM	Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial (GlobeNewswire)
Aug-01-24 04:05PM	Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -9.05% -5.67%
08:00AM	Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jul-29-24 05:00AM	Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients (GlobeNewswire) +122.52%
May-31-24 08:00AM	Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus (GlobeNewswire)
May-29-24 12:53PM	LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
08:00AM	Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-24-24 01:53PM	LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q4 2023 (InvestorPlace)
May-21-24 08:00AM	Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b (GlobeNewswire)
Apr-17-24 08:00AM	Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise (GlobeNewswire)
Apr-05-24 08:00AM	Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024 (GlobeNewswire)
Apr-03-24 08:00AM	Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis (GlobeNewswire)
Mar-07-24 03:23PM	PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease (GlobeNewswire)
Mar-05-24 08:00AM	Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline (GlobeNewswire) -21.57%
Feb-20-24 08:00AM	Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference (GlobeNewswire)
Dec-20-23 08:00AM	Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished (GlobeNewswire)
Nov-12-23 08:20PM	Lipella Pharmaceuticals gets ODD for LP-310 to treat GvHD (Pharmaceutical Business Review)
Nov-10-23 08:00AM	FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease (PR Newswire) -8.12%
Oct-25-23 04:05PM	Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) -24.89% -31.95%
Oct-24-23 08:00AM	Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Oct-23-23 08:45AM	Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing (PR Newswire)
08:30AM	Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference (ACCESSWIRE)
Oct-20-23 08:00AM	Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus (PR Newswire) +29.81%
Sep-21-23 08:30AM	Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology (PR Newswire)
Jun-13-23 08:30AM	Lipella Pharmaceuticals: Addressing Significant Unmet Need for Cancer Survivors, Delivering Long Term Value for Shareholders (NewMediaWire) +6.75%
May-15-23 09:15AM	Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update (PR Newswire)
May-14-23 08:12AM	Lipella Pharmaceuticals First Quarter 2023 Earnings: US$0.19 loss per share (vs US$0.19 loss in 1Q 2022) (Simply Wall St.)
May-01-23 08:30AM	Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual Meeting (PR Newswire) -20.90%
Apr-17-23 08:30AM	Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite (PR Newswire)
Apr-05-23 08:30AM	Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent (PR Newswire)
Mar-31-23 08:00AM	Lipella Provides Business Update and Reports 2022 Financial Results (PR Newswire) +5.98%
Mar-16-23 08:30AM	Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological Association (PR Newswire) +36.07%
Mar-01-23 08:00AM	Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board (PR Newswire)
Jan-11-23 07:30AM	Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10 (PR Newswire) +18.01%
Jan-09-23 08:00AM	Lipella Pharmaceuticals to Present at January 2023 Biotech Showcase in San Francisco (PR Newswire)
Dec-22-22 04:05PM	Lipella Announces Closing of Initial Public Offering for Gross Proceeds of $7 Million (PR Newswire) +12.78% -10.89%

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIPO

Lipella Pharmaceuticals Inc

Upgrade your FINVIZ experience